DALLAS - Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotech company with a current market capitalization of approximately $31 million, has unveiled promising preclinical data for its drug ...
CHARLOTTESVILLE, Va., Sept. 4, 2025 /PRNewswire/ -- RIVANNA®, developers of world-first imaging-based medical technologies, has been awarded a $2.21 million Small Business Innovation Research (SBIR) ...
Lantern Pharma was granted the rare pediatric disease designation (RPDD) for drug-candidate, LP-184, in three cancer indications: Malignant Rhabdoid Tumors, Rhabdomyosarcoma, and Hepatoblastoma. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results